跳至主要内容
临床试验/DRKS00008856
DRKS00008856已完成未知

Multicentre, prospective, randomised, blinded, placebo-controlled study to evaluate a novel medical device for long-lasting weight loss in overweight and obesity.

Praxis Dr. von Seck0 个研究点目标入组 21 人开始时间: 2015年7月28日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
21

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 95 Years(—)
性别
All

入选标准

  • 1.Age: 18 to 95 years
  • 2.Gender: Männer und Frauen
  • 3.BMI between 25 and 29.9 with concomitant obesity-related health disorders, an abdominal
  • fat distribution pattern, diseases which are aggravated by obesity or a high degree of psychosocial pressure.
  • 4.BMI = 30 kg / m2
  • 5.Capacity to consent
  • 6.Signed consent form
  • 7.Desire to reduce weight
  • 8.Failure of a basic program (nutritional, exercise and behavioural therapy), i. e. less than 5% weight reductiom / 3 to 6 months or weight regain

排除标准

  • 1.Weight reduction > 5% over the last months before inclusion into the study
  • 2.Individuals with denture, esp. worn with implants or pivot teeth
  • 3.Less than 10 teeth / joint, teeth with maximally mild to moderate paradontal Zähne pro Kiefer mit maximal leichter bis mittelschwerer paradontal defects
  • 4.Craniomandibular problems
  • 5.Wasting diseases
  • 6.Clinical diagnosis of an eating disorder
  • 7.Medication with substances influencing weight or appetite (i. e. steroids, psyotropic drugs, diuretics)
  • 8.Major surgical interventions durign the last 3 months
  • 9.Pregnancy or breastfeeding women
  • 10.Mental disorders or non-compliance
  • 11.Inability to take in meals on a regularly
  • 12.Incapacity to give informed consent
  • 13.Secondary causes of obesity, i.e. der Adipositas, wie hypothyrodism, cushings syndrome, hypogonadism, hypothalimic tumors, or metabolic decompensation in diabetes mellitus
  • 14.Newly diagnosed diabetes mellitus during the last 6 months before inclusion
  • 15.HbA1C > 9% in diabetics
  • 16.Uncontrolled arterial hypertension
  • 17.Initiation / change of medication for a chronic disease during the last 3 months before inclusion
  • 18.Participation in another clinical trial
  • 19.Participation in another weight reduction program in the last 3 months
  • 20.Unintended weight loss in the last 3 months
  • 21.Participation in another therapy program during the course of the study

研究者

发起方
Praxis Dr. von Seck

相似试验

招募中
不适用
Multicentre, prospective, randomised, double-blind, placebo-controlled study to evaluate the mechanism of a novel medical device for long-lasting weight loss in overweight and obesity.E66.9Obesity, unspecified
DRKS00008922Praxis Dr. med. von Seck15
进行中(未招募)
不适用
Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabetic neuropthic foot ulcerDiabetic neuropathic foot ulcerMedDRA version: 12.0Level: LLTClassification code 10012664Term: Diabetic foot ulcer
EUCTR2009-014276-22-CZaboratoires Genevrier388
进行中(未招募)
不适用
Prospective, randomised, multi-centre, blind-observer, controlled, parallel-group study comparing the efficacy and the safety of DERMAGEN® versus conventionnal treatment in the treatment of diabetic neuropthic foot ulcerDiabetic neuropathic foot ulcerMedDRA version: 12.0Level: LLTClassification code 10012664Term: Diabetic foot ulcer
EUCTR2009-014276-22-PLaboratoires Genevrier388
已完成
不适用
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of pelvic floor biofeedback training with ACTICORE1® for stress incontinence?N39.3Stress incontinence
DRKS00027319ACTICORE GmbH124
尚未招募
Unknown
Prospective, multicenter, randomized, controlled, single-blind other clinical trial. What is the efficacy of app-based biofeedback training with ACTICORE1® for female stress incontinence?N39.3Stress incontinence
DRKS00033971ACTICORE GmbH262